These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15057437)

  • 1. Polymer-sirolimus-eluting stents in de novo lesions.
    Schuler G
    Herz; 2004 Mar; 29(2):152-61. PubMed ID: 15057437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
    Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
    Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
    Buellesfeld L; Grube E
    Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting stents for in-stent restenosis and acute myocardial infarction: present data from nonrandomized studies.
    Schofer J; Bode C; Silber S
    Herz; 2004 Mar; 29(2):195-200. PubMed ID: 15057441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification and current treatment options of in-stent restenosis. Present status and future perspectives.
    Ong AT; Aoki J; McFadden EP; Serruys PW
    Herz; 2004 Mar; 29(2):187-94. PubMed ID: 15057440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymer-based paclitaxel-eluting coronary stents. Clinical results in de novo lesions.
    Chieffo A; Colombo A
    Herz; 2004 Mar; 29(2):147-51. PubMed ID: 15054587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-eluting stents: from randomized trials to the real world.
    Saia F; Degertekin M; Lemos PA; Serruys PW
    Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.
    Ge J; Qian J; Wang X; Wang Q; Yan W; Yan Y; Fan B; Ge L; Liu X
    Catheter Cardiovasc Interv; 2007 Feb; 69(2):198-202. PubMed ID: 17195205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PTCA with drug eluting stent. 90% fewer restenoses in high risk patients].
    MMW Fortschr Med; 2004 Aug; 146(33-34):53. PubMed ID: 15526636
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.
    Sabaté M; Jiménez-Quevedo P; Angiolillo DJ; Gómez-Hospital JA; Alfonso F; Hernández-Antolín R; Goicolea J; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Circulation; 2005 Oct; 112(14):2175-83. PubMed ID: 16203930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation. A post hoc analysis of TAXUS II.
    Silber S; Hamburger J; Grube E; Pfisterer M; Belardi J; Webb J; Zmudka K; Nienaber C; Hauptman K; Rutsch W; Dawkins K; Drzewiecki J; Koglin J; Colombo A
    Herz; 2004 Mar; 29(2):171-80. PubMed ID: 15057438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
    Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
    Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Position paper on the use of drug eluting stents (DES) in percutaneous coronary interventions in patients with coronary heart disease].
    Levenson B; ;
    Z Kardiol; 2003 Jul; 92(7):606-12. PubMed ID: 12883846
    [No Abstract]   [Full Text] [Related]  

  • 15. [Efficacy of sirolimus-eluting stents in diabetics with complex coronary lesions].
    Berenguer A; Mainar V; Bordes P; Valencia J; Gómez S
    Rev Esp Cardiol; 2006 Feb; 59(2):117-24. PubMed ID: 16540032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting stents: the panacea for restenosis?
    Lim MC
    Singapore Med J; 2004 Jul; 45(7):300-2. PubMed ID: 15221043
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating.
    Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
    Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB;
    Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.